Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Progesterone Resistance 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

pembrolizumab 1268Specimen Handling 871Carboplatin 831Magnetic Resonance Spectroscopy 805Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 630Radiotherapy 573Gemcitabine 571Biopsy 529Bevacizumab 476Dexamethasone 440fludarabine 406Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 358Fluorouracil 355atezolizumab 344durvalumab 333Rituximab 332Doxorubicin 317Radiosurgery 309Pemetrexed 306Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 284Radiation 281

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cyproterone acetate, ethinyl estradiol drug combination × 1 year × Clear all
NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Fudan University

Phase 2/3 Recruiting
80 enrolled
Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡